Partially matched transplants with allogeneic CD34+ blood cells

Tsutomu Watanabe, Shin Mineishi, Yoshifumi Kawano, Yoichi Takaue

Research output: Contribution to journalReview article

Abstract

Allogeneic CD34+ selected cell transplantation from a partially matched donor is feasible for the treatment of hematopoietic malignancies. Severe graft-versus-host disease (GvHD) can be prevented by this approach, and a lengthy search for an unrelated donor can be avoided. However, long-term engraftment is still a challenge, and may require intensified conditioning regimens with severe toxicities to sustain engraftment. Furthermore, unacceptable effects such as relapse and life-threatening viral infections might be more frequent after such transplants compared with non-T-cell-depleted transplants from an HLA-identical donor. Strict indications should be considered for this treatment based on a risk/benefit assessment for very high-risk patients. The early application of periodic donor leukocyte infusion (DLI) may be useful for preventing both late graft rejection and serious viral infections.

Original languageEnglish (US)
Pages (from-to)487-496
Number of pages10
JournalLeukemia and Lymphoma
Volume37
Issue number5-6
DOIs
StatePublished - Jan 1 2000

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Partially matched transplants with allogeneic CD34<sup>+</sup> blood cells'. Together they form a unique fingerprint.

  • Cite this